Finally, dysregulation of the p53-MDM2 pathway contributes as MDM2 overexpression leads to the degradation of p53, inhibiting tumor suppression and increasing MYCN activity, thus contributing to poor prognosis and resistance to therapy (51, 52). This evidence concerns the gene MDM2 and neoplasm.